Corcept Therapeutics Q3 revenue beats estimates on strong Lifyorli uptake

Overview

• US biopharma company's Q3 revenue rose 64% yr/yr, beating analyst expectations

• Q3 net income surged to $126.8 mln from $19.7 mln a year earlier

• Diluted EPS for Q3 rose to $1.01 from $0.16 yr/yr

Outlook

• Corcept reiterates 2026 revenue guidance of $1.1–$1.2 bln

• Company expects European Commission approval for relacorilant plus nab-paclitaxel by year-end

Result Drivers

• CUSHING'S SYNDROME DEMAND - Co said increased awareness and diagnosis of Cushing’s syndrome drove growth in its endocrinology business

• LIFYORLI LAUNCH - Rapid and broad uptake of Lifyorli in ovarian cancer contributed to revenue growth, per CEO

• KORLYM GROWTH - Korlym and authorized generic revenue rose 20% yr/yr to $249.1 mln as increased awareness and diagnosis of Cushing's syndrome supported demand

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Corcept Therapeutics Incorporated is $162.50, about 102% above its November 2 closing price of $80.46

• The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 38 three months ago

Reuters Recommended Reads

• Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised

• Nov 2 - BioMarin Q3 revenue rises on Amicus acquisition, adjusted EPS beats

• Nov 3 - Pfizer Q3 revenue beats estimates on new launches; raises guidance

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)